Levels of soluble FasL and FasL gene expression during the development of graft-versus-host disease in DLT-treated patients

British Journal of Haematology

Volumn 104, Issue 4, 1999, Pages 795-800

  Das, Hiranmoy ^a   Imoto, Shion ^a   Murayama, Tohru ^a   Kajimoto, Kazuyoshi ^a   Sugimoto, Takeshi ^a   Isobe, Takashi ^b   Nakagawa, Toshitaro ^a   Nishimura, Ryuichiro ^a   Koizumi, Tamio ^a,c  

^a Hyogo College of Medicine   (Japan)

^b KOBE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c Hyogo Institute of Clinical Research   (Japan)

Author keywords

BMT; DLT; FasL gene expression; GVHD; sFasL

Indexed keywords

FAS LIGAND; METHYLPREDNISOLONE;

ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CASE REPORT; FEMALE; GENE EXPRESSION; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LEUKEMIA; LYMPHOCYTE TRANSFUSION; MALE; MONONUCLEAR CELL; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN EXPRESSION;

EID: 0033038135     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.1999.01246.x     Document Type: Article

References (25)

1. Adachi, M., Suematsu, S., Suda, T., Watanabe, D., Fukuyama, H., Ogasawara, J., Tanaka, T., Yoshida, N. & Nagata, S. (1996) Enhanced and accelerated lymphoproliferation in Fas-null mice. Proceedings of the National Academy of Sciences of the United States of America, 93, 2131-2136.
2. Baker, M.B., Altman, N.H., Podack, E.R. & Levy, R.B. (1996) The role of cell-mediated cytotoxicity in acute GVHD after MHC-matched allogeneic bone marrow transplantation in mice. Journal of Experimental Medicine, 183, 2645-2656.
3. Baker, M.B., Riley, R.L., Podack, E.R. & Levy, R.B. (1997) Graft-versus-host-disease-associated lymphoid hypoplasia and B cell dysfunction is dependent upon donor T cell-mediated Fas-ligand function, but not perforin function. Proceedings of the National Academy of Sciences of the United States of America, 94, 1366-1371.
4. Braun, M.Y., Lowin, B., French, L., Acha-Orbea, H. & Tschopp, J. (1996) Cytotoxic T cells deficient in both functional Fas ligand and perforin show residual cytolytic acitivity yet lose their capacity to induce lethal acute graft-versus-host disease. Journal of Experimental Medicine, 183, 657-661.
5. Chu, J.L., Ramos, P., Rosendorff, A., Nikolic-Zugic, J., Lacy, E., Matsuzawa, A. & Elkon, K.B. (1995) Massive upregulation of the Fas ligand in Ipr and gld mice: implications for Fas regulation and the graft-versus-host disease-like wasting syndrome. Journal of Experimental Medicine, 181, 393-398.
6. Cross, H.J. & Dower, S.K. (1995) Tumor necrosis factor ligand superfamily: involvement in the pathology of malignant lymphoma. Blood, 85, 3378-3404.
7. Hakim, F.T. & Mackall, C.L. (1997) The immune system: effector and target of graft-versus-host disease. Graft-vs-Host Disease (ed. by J. L. M. Ferrara, H. J. Deeg and S. J. Burakoff), pp. 257-289. Marcel Dekker, New York.
8. Hattori, K., Hirano, T., Miyajima, H., Yamakawa, N., Tateno, M., Oshimi, K., Kayagaki, N., Yagita, H. & Okumura, K. (1998) Differential effects of anti-Fas ligand and anti-tumor necrosis factor α antibodies on acute graft-versus-host disease pathologies. Blood, 91, 4051-4055.
9. Hayashi, N. & Mita, E. (1997) Fas system and apoptosis in viral hepatitis. Journal of Gastroenterology and Hepatology, 12, S223-S226.
10. Liem, L.M., van Lopik, T., van Nieuwenhuijze, A.E.M., van Houwelingen, H.C., Aarden, L. & Goulmy, E. (1998) Soluble Fas levels in sera of bone marrow transplantation recipients are increased during acute graft-versus-host disease but not during infections. Blood, 91, 1464-1468.
11. Nagata, S. (1997) Apoptosis by death factor. Cell, 88, 355-365.
12. Nagata, S. & Golstein, P. (1995) The Fas death factor. Science, 267, 1449-1456.
13. Nagata, S. & Suda, T. (1995) Fas and Fas ligand: Ipr and gld mutations. Immunology Today, 16, 39-43.
14. Piguet, P.F., Grau. G.E., Allet, B. & Vassalli, P. (1987) Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-vs-host disease. Journal of Experimental Medicine, 166, 1280-1289.
15. Storb, R. & Thomas, H.D. (1985) Graft-versus-host disease in dog and man: the Seattle experience. Immunological Reviews, 88, 215-238.
16. Suda, T., Takahashi, T., Golstein, P. & Nagata, S. (1993) Molecular cloning and expression of Fas ligand: a novel member of the tumor necrosis factor family. Cell, 75, 1169-1178.
17. Suda, T., Tanaka, M, Miwa, K. & Nagata, S. (1996) Apoptosis of mouse naive T cells induced by recombinant soluble fas ligand and activation-induced resistance to Fas ligand. Journal of Immunology, 157, 3918-3924.
18. Tanaka, M., Itai, T., Adachi, M. & Nagata, S. (1998) Downregulation of Fas ligand by shedding. Nature Medicine, 4, 31-36.
19. Tanaka, M., Suda, T., Haze, K., Nakamura, N., Sato, K., Kimura, F., Motoyoshi, K., Mizuki, M., Tagawa, S., Ohga, S., Hatake, K., Drummond, A.H. & Nagata, S. (1996) Fas ligand in human serum. Nature Medicine, 2, 317-322.
20. Tanaka, M., Suda, T., Takahashi, T. & Nagata, S. (1995) Expression of the functional soluble form of human Fas ligand in activated lymphocytes. EMBO Journal, 14, 1129-1135.
21. Tanaka, M., Suda, T., Yatomi, T., Nakamura, N. & Nagata, S. (1997) Lethal effect of recombinant human Fas ligand in mice pretreated with Propionibacterium acnes. Journal of Immunology, 158, 2303-2309.
22. Theofilopoulos, A.N., Balderas, R.S., Gozes, Y., Aguado, M.T., Hang, L-M., Morrow, P.R. & Dixon, F.J. (1985) Association of Ipr gene with graft-vs-host disease-like syndrome. Journal of Experimental Medicine, 162, 1-18.
23. Via, C.S., Nguyen, P., Shustov, A., Drappa, J. & Elkon, K.B. (1996) A major role for the Fas pathway in acute graft-versus-host disease. Journal of Immunology, 157, 5387-5393.
24. Vignaux, F., Vivier, E., Malissen, B., Dapraetere, V., Nagata, S. & Golstein, P. (1995) TCR/CD3 coupling to Fas-based cytotoxicity. Journal of Experimental Medicine, 181, 781-786.
25. Watanabe-Fukunaga, R., Brannan, C.I., Itoh, N., Yonehara, S., Copeland, N.G., Jenkins, N.A. & Nagata, S. (1992) The cDNA structure, expression and chromosomal assignment of the mouse Fas antigen. Journal of Immunology, 148, 1274-1279.